WO2017033020A1 - Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto - Google Patents

Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto Download PDF

Info

Publication number
WO2017033020A1
WO2017033020A1 PCT/GB2016/052647 GB2016052647W WO2017033020A1 WO 2017033020 A1 WO2017033020 A1 WO 2017033020A1 GB 2016052647 W GB2016052647 W GB 2016052647W WO 2017033020 A1 WO2017033020 A1 WO 2017033020A1
Authority
WO
WIPO (PCT)
Prior art keywords
binding member
binding
lewis
sialyl
member according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2016/052647
Other languages
English (en)
French (fr)
Inventor
Lindy Gillian DURRANT
Mireille VANKEMMELBEKE
Silvana TIVADAR
Tina Parsons
Richard Mcintosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nottingham
Original Assignee
University of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020187008554A priority Critical patent/KR102713512B1/ko
Priority to US15/754,882 priority patent/US10835618B2/en
Priority to ES16760541T priority patent/ES2788159T3/es
Priority to BR112018003779-6A priority patent/BR112018003779A2/pt
Priority to JP2018510883A priority patent/JP6928602B2/ja
Priority to DK16760541.9T priority patent/DK3341412T3/da
Application filed by University of Nottingham filed Critical University of Nottingham
Priority to EP16760541.9A priority patent/EP3341412B1/en
Priority to CN201680056234.5A priority patent/CN108137695B/zh
Priority to CA2996436A priority patent/CA2996436A1/en
Publication of WO2017033020A1 publication Critical patent/WO2017033020A1/en
Anticipated expiration legal-status Critical
Priority to ZA2018/01994A priority patent/ZA201801994B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Definitions

  • GLYCOLIPIDS AS A FUNCTIONAL CANCER TARGET AND ANTIBODIES
  • the present invention relates to targeting of sialyl-di-Lewis a in cancer and binding members, such as monoclonal antibodies (mAbs), which bind this glycan as expressed on glycoproteins but not lipids.
  • mAbs monoclonal antibodies
  • Glycan structures are present on both protein and glycolipid backbones and can be massively over-expressed in cancer due to altered expression of glycosyltransferases.
  • proteins in the ER are decorated with a branched 9 mannose sugar (man) 9 complex.
  • mannosidase I removes 4 of the mannose sugars (man) 5 and then mannosidases II removes a further 2 (man) 3 .
  • Glycosyltransferases then build complex glycan structures on this mannose core. These glycans are vital for folding and the function of the proteins.
  • Generating mAbs to glycans expressed on proteins is a problem, as the mAbs rarely see just the small glycan but usually recognise the glycan on the specific protein giving a very restrictive expression.
  • TACAs tumour-associated carbohydrate antigens
  • Lewis carbohydrates are ideal candidates for mAb therapy as they have a very limited distribution on normal tissues and are over-expressed in cancers that originated from epithelial cells, particularly in pancreatic and gastrointestinal cancer. They are formed by the sequential addition of fucose onto oligosaccharide precursor chains on glycoproteins and glycolipids, through the action of glycosyltransferases and can be divided in type I chains - which form Le a and Le b and type II chains - which form Lewis x and Lewis y .
  • Sialyl-Lewis a is a ligand of E-selectin involved in endothelial leukocyte adhesion and is over-expressed in cancers of the hepato-biliary system, pancreas and gastrointestinal tract, while its natural form, di- sialyl-Lewis 3 which has an extra sialic acid sugar, is found in non- malignant epithelial cells. Expression of sialyl-Lewis 3 was found to increase metastatic potential in pancreatic adenocarcinoma (16, 27) and colon cancer (14, 15). In pancreatic and colon cancer, sialyl-Lewis 3 is also used as a tumour marker to monitor responses to therapy (13,17, 18).
  • Sialyl-di-Lewis 3 (this has the single sialic acid found in cancers but also has the Lewis 3 duplicated and is only found on proteins), is expressed by a wide range of pancreatic tumours but has a very restricted normal tissue expression. More recently, human sialyl- Lewis 3 mAbs were produced using a patient vaccination strategy that showed specific binding to sialyl-Lewis 3 and exhibited ADCC, CDC and anti-tumour activity in a xenograft model (20).
  • One of these mabs, 5B1 is a human IgGl which predominantly binds Sialyl Lewis 3 whether the neuraminic acid is endogenously produced (N-acetyl-neuraminic acid) or exogenously derived (N-glycolyl-neuraminic acid) and whether it is on a long or short spacer. Binding to Sialyl-di-lewis 3 or Sialyl lewis 3"x is weak and insignificant.
  • the second mab 7E3 is a human IgM which binds equally to Sialyl lewis 3 whether the neuraminic acid is endogenously produced (N acetyl neuraminic acid) or exogenously derived (N-glycolyl- neuraminic acid) and whether it is on a long or short spacer, and to Sialyl-di-lewis 3 or Sialyl lewis 3"x .
  • Such anti-Sialyl Lewis 3 mabs would have an unacceptable normal distribution, which is supported by the observation that GivaRex (a mouse monoclonal antibody) and its patent (WO0191792) has been abandoned in preclinical studies.
  • An aim of the present invention is to provide an improved binding member for sialyl-di- Lewis 3 .
  • an isolated specific binding member capable of binding sialyl-di-Lewis 3 .
  • the binding member may be specific for sialyl-di-Lewis 3 . In one embodiment, the binding member may be specific for sialyl-di-Lewis 3 and sialyl-Lewis 3"x . The binding member may be specific for sialyl-di-Lewis 3 . In one embodiment, the binding member may be specific for sialyl-di-Lewis 3 and sialyl-Lewis 3"x present in tumour tissue. The binding member may not bind, or may not significantly bind, mono-sialyl-Lewis 3 bound to a glycolipid. Additionally or alternatively, the binding member may not bind, or may not significantly bind, di-sialyl- Lewis 3 . The binding member may not bind, or may not significantly bind, di-sialyl-Lewis a present in healthy (non-tumour) tissue.
  • Synthetic (i.e. non-natural) molecules may be provided for characterizing the binding member binding specificity.
  • Such forms may comprise any one of sialyl-di-Lewis a , sialyl- Lewis a"x , di-sialyl-Lewis a or mono-sialyl-Lewis a molecules presented on a protein or lipid (e.g. a glycoprotein or glycolipid).
  • the synthetic molecule may comprise sialyl-Lewis a with exogenously derived N-glycolyl-neuraminic acid or endogenously derived N-acetyl- neuraminic acid.
  • the binding member may bind mono-sialyl-Lewis a , wherein the mono-sialyl-Lewis a is presented on a glycoprotein.
  • the binding member may be specific for sialyl-di-Lewis a , sialyl-Lewis a"x and mono-sialyl-Lewis a , wherein the mono- sialyl-Lewis 3 is presented on a glycoprotein.
  • the mono-sialyl-Lewis a may be linked to the protein by a spacer, such as a polymer.
  • the polymer may comprise any natural or synthetic molecule that allows sialyl-Lewis a to bind into a groove of the binding member.
  • the polymer chain may comprise a glycan chain or amino acid (i.e. a polypeptide).
  • the glycan chain linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 4 glycan monomer units.
  • the glycan chain linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 5 glycan monomer units.
  • the glycan chain linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 6 glycan monomer units.
  • the glycan chain linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 7 glycan monomer units.
  • the glycan chain linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 8 glycan monomer units.
  • the polypeptide linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 4 amino acids.
  • the polypeptide linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 5 amino acids.
  • the polypeptide linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 6 amino acids.
  • the polypeptide linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 7 amino acids.
  • the polypeptide linking the mono-sialyl-Lewis a to the glycoprotein may comprise at least 8 amino acids.
  • the present invention advantageously provides a binding member, such as a monoclonal antibody, that shows a high specificity for sialyl-di-Lewis a and sialyl-Lewis a"x . It can also bind to mono-sialyl-Lewis a when it is linked to a glycoprotein by a glycan chain, suggesting that it requires at least 4 carbohydrates presented in the correct conformation to bind and a spacer (such as a glycan chain) to allow insertion into the antibody groove.
  • This constraint in contrast to other mono-sialyl-Lewis a binding maAbs, gives it the unique ability to bind to glycoproteins but not glycolipids.
  • the binding member may not bind to glycolipid bound Sialyl lewis 3 as the lipid is too hyrophobic to allow insertion of the glycan into the deep antibody groove.
  • the invention herein has provided, characterised and chimerised a binding member, such as FG129 mAb.
  • This mAb targets the novel glycan, sialyl-di-Lewis 3 (this has the single sialic acid found in cancers but also has the Lewis 3 duplicated and is only found on proteins), which is expressed by a wide range of pancreatic tumours but has a very restricted normal tissue expression.
  • Chimeric FG129 (CH129) induces strong ADCC and CDC responses on tumours, suggesting the antigen is a good target for immune mediated killing. This can be further potentiated by redirecting T cell killing by recombination of FG129 with a second mAb recognising and activating T cells.
  • a further application of the humanised mAb is in the generation of a bispecific mAb targeting the FG129 and CD3 antigens.
  • the indication for such a bispecific could be but is not restricted to pancreatic cancer.
  • the mAb FG129 also internalised and delivered drugs which efficiently killed tumour cells, demonstrating its ADC potential.
  • the invention also provides isolated specific binding member capable of binding sialyl-di- Lewis 3 and sialyl-Lewis 3"x Neu5Aca2-3Galbl-3(Fucal-4)GlcNAcbl-3Galbl-4(Fucal- 3)GlcNAcb- and mono-sialyl-Lewis 3 Neu5Aca2-3Galbl-3(Fucal-4)GlcNAcb-only attached to a glycoprotein.
  • binding members may be for use in a method for treating cancer.
  • the invention also provides for the use of such a binding partner in the manufacture of a medicament for the treatment of cancer.
  • the invention also provides a method of treating cancer, comprising administering a binding partner of the invention to a subject in need of such treatment.
  • the present invention provides the mAb FG129 which binds to sialyl-di- Lewis 3 and sialyl-Lewis a"x and mono-sialyl-Lewis a only attached to a glycoprotein.
  • the present invention provides the chimeric hlgGl 129 which binds to sialyl-di-Lewis a and sialyl-Lewis a"x and mono-sialyl-Lewis a only attached to a glycoprotein.
  • the binding member may be capable of binding to some pancreatic tumours, for example at least 70% or 74% of pancreatic tumours in a population of patients.
  • the binding member may be capable of binding to some gastric tumours, for example at least 45% or 50% of gastric tumours in a population of patients.
  • the binding member may be capable of binding to some colorectal tumours, for example at least 30% or 36% of colorectal tumours in a population of patients.
  • the binding member may be capable of binding to some ovarian tumours, for example at least 25% or 27% of ovarian tumours in a population of patients.
  • the binding member may be capable of binding to some non small cell lung cancers, for example at least 5% or 7% of non small cell lung cancers in a population of patients.
  • the tumour tissue binding of the binding member may be assessed by immunohistochemistry (IHC) on tumour tissue microarrays (TMAs).
  • the binding member does not bind, or does not significantly bind to non-cancerous tissue, such as non-cancerous heart, brain, stomach, or kidney tissue. Additionally or alternatively, the binding member has low affinity for, or does not significantly bind to non-cancerous tissue of the gallbladder, ileum, liver, lung, oesophagus, pancreas, skin or thymus.
  • the binding member may be capable of binding to glycoprotein-presented sialyl-Lewis a with an affinity (KD) of less than about 10 "6 M.
  • the binding member may be capable of binding to glycoprotein-presented sialyl-Lewis a with an affinity (KD) of less than about 10 "7 M.
  • the binding member may be capable of binding to glycoprotein-presented sialyl-Lewis a with an affinity (KD) of less than about 10 "8 M, 10 "9 M, 10 "10 M, 10 "n M or 10 "12 M.
  • the binding member may be capable of binding to glycoprotein-presented sialyl -Lewis 3 with an affinity (KD) of less than about 10 "13 M.
  • the binding member may be capable of binding to glycoprotein-presented sialyl-Lewis a with a dissociation rate (Kd) of 10 "8 1/s or less.
  • the binding member may be capable of binding to glycoprotein-presented sialyl-Lewis a with an association rate (Ka) of at least about 10 4 1/Ms. Binding affinity may be measured by surface plasmon resonance Biacore X.
  • a further aspect of the invention provides an isolated specific binding member comprising heavy chain binding domains CDR1, CDR2 and CDR3, and light chain binding domains CDR1, CDR2, and CDR3.
  • the invention may provide an isolated specific binding member comprising one or more binding domains selected from the amino acid sequence of residues 26 to 33 (CDRHl), 50-59 (CDRH2) and 98 to 106 (CDRH3) of Figure la or 2a.
  • the binding domain may comprise an amino acid sequence substantially as set out as 1- 117 (VH) of Figures la or 2a.
  • the member comprises a binding domain which comprises an amino acid sequence substantially as set out as residues 98 to 106 (CDRH3) of the amino acid sequence of Figure la or 2a.
  • the isolated specific binding member may additionally comprise one or both, preferably both, of the binding domains substantially as set out as residues 26 to 33 (CDRHl) and residues 50-59 (CDRH2) of the amino acid sequence shown in Figure la and 2a.
  • the present invention provides an isolated specific binding member comprising one or more binding domains selected from the amino acid sequence of residues 27 to 38 (CDRL1), 56-58 (CDRL2) and 95 to 103 (CDRL3) of Figure lb or 2b.
  • the binding domain may comprise an amino acid sequence substantially as set out as residues 95 to 103 (CDRL3) of the amino acid sequence of Figure lb and 2b.
  • the isolated specific binding member may additionally comprise one or both, preferably both, of the binding domains substantially as set out as residues 27 to 38 and (CDRLl) residues 56 to 58 of (CDRL2) the amino acid sequence shown in Figure lb and 2b.
  • variable heavy and/or ligh chain may comprise HCDRl-3 and LCDRl-3 of antibody FG129. In another embodiment, the variable heavy and/or ligh chain may comprise HCDRl-3 and LCDRl-3 of antibody FG129, and framework regions of FG129.
  • binding members which comprise a plurality of binding domains of the same or different sequence, or combinations thereof, are included within the present invention.
  • Each binding domain may be carried by a human antibody framework.
  • one or more framework regions may be substituted for the framework regions of a whole human antibody or of the variable region thereof.
  • One isolated specific binding member of the invention comprises the sequence substantially as set out as residues 1 to 114 (VL) of the amino acid sequence shown in Figure lb or 2b.
  • binding members having sequences of the CDRs of Figure la or figure 2a may be combined with binding members having sequences of the CDRs of Figure lb or 2b.
  • the binding member may comprise a light chain variable sequence comprising LCDR1, LCDR2 and LCDR3, wherein
  • LCDR1 comprises QSLLNSGNQKNY,
  • LCDR2 comprises WAS
  • LCDR3 comprises Q DYSSPFT
  • a heavy chain variable sequence comprising HCDR1, HCDR2 and HCDR3, wherein
  • HCDR2 comprises IRSKSNNYAT, and
  • HCDR3 comprises VGYGSGGNY.
  • the invention provides a binding member comprising a VH domain comprising residues 1 to 117 of the amino acid sequence of Figure la or 2a, and a VL domain comprising residues 1 to 114 of the amino acid sequence of Figure lb or 2b.
  • the invention also encompasses binding partners as described above, but in which the sequence of the binding domains are substantially as set out in Figures 1 or 2.
  • binding partners as described above are provided, but in which in one or more binding domains differ from those depicted in Figures 1 or 2 by from 1 to 5, from 1 to 4, from 1 to 3, 2 or 1 substitution.
  • the invention also encompasses binding partners having the capability of binding to the same epitopes as the VH and VL sequences depicted in Figures 1 and 2.
  • the epitope of a mAb is the region of its antigen to which the mAb binds.
  • Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the antigen. That is, a lx, 5x, lOx, 20x or lOOx excess of one antibody inhibits binding of the other by at least 50% but preferably 75%, 90% or even 99% as measured in a competitive binding assay compared to a control lacking the competing antibody (see, e.g., Junghans et al., Cancer Res. 50: 1495, 1990, which is incorporated herein by reference).
  • the invention therefore further provides a binding member which competes for binding to sialyl-di-Lewis a and sialyl-Lewis a"x and mono-sialyl-Lewis a only attached to a glycoprotein with an antibody comprising a VH chain having the amino acid sequence of residues 1 to 117 of Figure la or 2a and a VL chain having the amino acid sequence of residues 1 to 114 of Figure lb or 2b.
  • the competing binding partner competes for binding to to sialyl-di-Lewis a only attached to a glycoprotein with an antibody comprising a VH chain having the amino acid sequence of residues 1 to 117 of Figure la or 2a and a VL chain having the amino acid sequence of residues 1 to 114 of Figure lb or 2b.
  • the competing binding partner competes for binding to sialyl-di- Lewis 3 and sialyl-Lewis a"x and mono-sialyl-Lewis a only attached to a glycoprotein with an antibody comprising a VH chain having the amino acid sequence of residues 1 to 117 of Figurela and a VL chain having the amino acid sequence of residues 1 to 114 of Figure lb, or with an antibody comprising a VH chain having the amino acid sequence of residues 1 to 117 of Figure 2a and a VL chain having the amino acid sequence of residues 1 to 114 of Figure 2b.
  • competing binding partners are antibodies, for example monoclonal antibodies, or any of the antibody variants or fragments mentioned throughout this document.
  • archtypal mAb for example an FG129 mAb
  • the heavy chain of the archtypal antibody is paired with a repertoire of (preferably human) light chains to select a glycan-binding mAb, and then the new light chain is paired with a repertoire of (preferably human) heavy chains to select a (preferably human) glycan-binding mAb having the same epitope as the archtypal mAb.
  • MAbs that are capable of binding sialyl-di-Lewis a and sialyl-Lewis a"x and mono-sialyl- Lewis a only attached to a glycoprotein and i nduc e AD C C or intern al i z e and are at least 90%, 95% or 99% identical in the VH and/or VL domain to the VH or VL domains of Figures 1 or 2, are included in the invention.
  • Reference to the 90%, 95%, or 99% identity may be to the framework regions of the VH and/or VL domains.
  • the CDR regions may be identical, but the framework regions may vary by up to 1%, 5%, or 10%).
  • the specific binding pair may be an antibody or an antibody fragment, Fab, (Fab')2, scFv, Fv, dAb, Fd or a diabody.
  • the antibody is a polyclonal antibody. In other embodiments the antibody is a monoclonal antibody.
  • Antibodies of the invention may be humanised, chimeric or veneered antibodies, or may be non-human antibodies of any species.
  • the specific binding partner of the invention is mouse antibody FG129 which comprises a heavy chain as depicted in Figure la and a light chain as depicted in Figure lb.
  • the specific binding partner of the invention is chimeric antibody FG129 which comprises a heavy chain as depicted in Figure 2a and a light chain as depicted in Figure 2b.
  • Specific binding members of the invention may carry a detectable or functional label.
  • the invention provides an isolated nucleic acid which comprises a sequence encoding a specific binding member of the aspects of the invention, and methods of preparing specific binding members of the invention which comprise expressing said nucleic acids under conditions to bring about expression of said binding member, and recovering the binding member.
  • Specific binding members according to the invention may be used in a method of treatment or diagnosis of the human or animal body, such as a method of treatment of a tumour in a patient (preferably human) which comprises administering to said patient an effective amount of a specific binding member of the invention.
  • the invention also provides a specific binding member of the present invention for use in medicine, as well as the use of a specific binding member of the present invention in the manufacture of a medicament for the diagnosis or treatment of a tumour.
  • the invention also provides the antigen to which the specific binding members of the present invention bind.
  • a sialyl-di-Lewis a which is capable of being bound, preferably specifically, by a specific binding member of the present invention is provided.
  • the sialyl-di-Lewis a may be provided in isolated form, and may be used in a screen to develop further specific binding members therefor.
  • a library of compounds may be screened for members of the library which bind specifically to the sialyl-di-Lewis a .
  • the sialyl-di-Lewis a may on a protein backbone. When on a protein backbone, it may have a molecular weight of about 50-150kDa, as determined by SDS- PAGE.
  • the invention provides an isolated specific binding member capable of specifically binding sialyl-di-Lewis a and sialyl-Lewis a"x for use in the diagnosis or prognosis of colorectal, gastric, pancreatic, lung, ovarian and breast tumours.
  • the invention provides an isolated specific binding member capable of specifically binding sialyl-di-Lewis a and sialyl-Lewis a"x and mono-sialyl-Lewis a only attached to a glycoprotein for use in the diagnosis or prognosis of colorectal, gastric, pancreatic, lung, ovarian and breast tumours.
  • the invention further provides a method for diagnosis of cancer comprising using a specific binding partner of the invention to detect sialyl-di-Lewis a and sialyl-Lewis a"x and mono-sialyl-Lewis a only attached to a glycoprotein in a sample from an individual.
  • a specific binding partner of the invention to detect sialyl-di-Lewis a and sialyl-Lewis a"x and mono-sialyl-Lewis a only attached to a glycoprotein in a sample from an individual.
  • the pattern of glycans detected by the binding partner is used to stratify therapy options for the individual.
  • a “specific binding member” is a member of a pair of molecules which have binding specificity for one another.
  • the members of a specific binding pair may be naturally derived or wholly or partially synthetically produced.
  • One member of the pair of molecules has an area on its surface, which may be a protrusion or a cavity, which specifically binds to and is therefore complementary to a particular spatial and polar organisation of the other member of the pair of molecules.
  • the members of the pair have the property of binding specifically to each other.
  • types of specific binding pairs are antigen-antibody, biotin-avidin, hormone-hormone receptor, receptor- ligand, enzyme- substrate.
  • the present invention is generally concerned with antigen- antibody type reactions, although it also concerns small molecules which bind to the antigen defined herein.
  • treatment includes any regime that can benefit a human or non-human animal, preferably mammal.
  • the treatment may be in respect of an existing condition or may be prophylactic (preventative treatment).
  • Tumour is an abnormal growth of tissue. It may be localised (benign) or invade nearby tissues (malignant) or distant tissues (metastatic). Tumours include neoplastic growths which cause cancer and include oesophageal, colorectal, gastric, breast and endometrial tumours, as well as cancerous tissues or cell lines including, but not limited to, leukaemic cells. As used herein, “tumour” also includes within its scope endometriosis.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen, whether natural or partly or wholly synthetically produced.
  • the term also covers any polypeptide or protein having a binding domain which is, or is homologous to, an antibody binding domain. These can be derived from natural sources, or they may be partly or wholly synthetically produced.
  • antibodies are the immunoglobulin isotypes (e.g., IgG, IgE, IgM, IgD and IgA) and their isotypic subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; and diabodies.
  • Antibodies may be polyclonal or monoclonal. A monoclonal antibody may be referred to as a "mAb".
  • antibody should be construed as covering any specific binding member or substance having a binding domain with the required specificity.
  • this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, humanised antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic. Chimeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. Cloning and expression of chimeric antibodies are described in EP- A-0120694 and EP-A-0125023.
  • a humanised antibody may be a modified antibody having the variable regions of a non- human, e.g., murine, antibody and the constant region of a human antibody. Methods for making humanised antibodies are described in, for example, US Patent No. 5225539.
  • binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CHI domains; (ii) the Fd fragment consisting of the VH and CHI domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment [25] which consists of a VH domain; (v) isolated CDR regions; (vi) F(ab')2 fragments, a bivalent fragment comprising two linked Fab fragments; (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site [26, 27]; (viii) bispecific single chain Fv dimers (PCT/US92/09965) and; (ix) "diabodies", multivalent or multispecific fragments constructed by gene
  • Diabodies are multimers of polypeptides, each polypeptide comprising a first domain comprising a binding region of an immunoglobulin light chain and a second domain comprising a binding region of an immunoglobulin heavy chain, the two domains being linked (e.g., by a peptide linker) but unable to associated with each other to form an antigen binding site: antigen binding sites are formed by the association of the first domain of one polypeptide within the multimer with the second domain of another polypeptide within the multimer (WO94/13804).
  • bispecific antibodies may be conventional bispecific antibodies, which can be manufactured in a variety of ways [29], e.g., prepared chemically or from hybrid hybridomas, or may be any of the bispecific antibody fragments mentioned above. It may be preferable to use scFv dimers or diabodies rather than whole antibodies. Diabodies and scFv can be constructed without an Fc region, using only variable domains, potentially reducing the effects of anti-idiotypic reaction.
  • bispecific antibodies include the single chain “Janusins” described in [30].
  • Bispecific diabodies as opposed to bispecific whole antibodies, may also be useful because they can be readily constructed and expressed in E. coli.
  • Diabodies (and many other polypeptides such as antibody fragments) of appropriate binding specificities can be readily selected using phage display (WO94/13804) from libraries. If one arm of the diabody is to be kept constant, for instance, with a specificity directed against antigen X, then a library can be made where the other arm is varied and an antibody of appropriate specificity selected.
  • an “antigen binding domain” is the part of an antibody which comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antibody may only bind to a particular part of the antigen, which part is termed an epitope.
  • An antigen binding domain may be provided by one or more antibody variable domains.
  • An antigen binding domain may comprise an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).
  • VL antibody light chain variable region
  • VH antibody heavy chain variable region
  • an antigen binding domain is specific for a particular epitope which is carried by a number of antigens, in which case, the specific binding member carrying the antigen binding domain will be able to bind to the various antigens carrying the epitope.
  • Isolated refers to the state in which specific binding members of the invention or nucleic acid encoding such binding members will preferably be, in accordance with the present invention.
  • Members and nucleic acid will generally be free or substantially free of material with which they are naturally associated such as other polypeptides or nucleic acids with which they are found in their natural environment, or the environment in which they are prepared (e.g., cell culture) when such preparation is by recombinant DNA technology practised in vitro or in vivo.
  • Specific binding members and nucleic acid may be formulated with diluents or adjuvants and still for practical purposes be isolated - for example, the members will normally be mixed with gelatin or other carriers if used to coat microtitre plates for use in immunoassays, or will be mixed with pharmaceutically acceptable carriers or diluents when used in diagnosis or therapy.
  • Specific binding members may be glycosylated, either naturally or by systems of heterologous eukaryotic cells, or they may be (for example if produced by expression in a prokaryotic cell) unglycosylated.
  • the invention also includes within its scope polypeptides having the amino acid sequence as set out in Figure 1 or 2, polynucleotides having the nucleic acid sequences as set out in Figure A or B and sequences having substantial identity thereto, for example, 70%, 80%, 85%, 90%, 95% or 99% identity thereto.
  • the percent identity of two amino acid sequences or of two nucleic acid sequences is generally determined by aligning the sequences for optimal comparison purposes ⁇ e.g., gaps can be introduced in the first sequence for best alignment with the second sequence) and comparing the amino acid residues or nucleotides at corresponding positions.
  • the "best alignment" is an alignment of two sequences that results in the highest percent identity.
  • the determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art.
  • An example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul (1990) [31], modified as in Karlin and Altschul (1993) [32].
  • the BLAST and XBLAST programs of Altschul et al. (1990) [33] have incorporated such an algorithm.
  • Gapped BLAST can be utilized as described in Altschul et al. (1997) [34].
  • PSI-Blast can be used to perform an iterated search that detects distant relationships between molecules (Id.).
  • the default parameters of the respective programs ⁇ e.g., XBLAST and BLAST
  • Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, [35].
  • the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package has incorporated such an algorithm.
  • Isolated specific binding members of the present invention are capable of binding to a sialyl-di-Lewis a carbohydrate, which may be a sialyl-di-Lewis a on a protein moiety.
  • the CDR3 regions comprising the amino acid sequences substantially as set out as residues 98-106 (CDRH3) of Figure la and 2a and 95 to 103 of Figure lb and 2b, are carried in a structure which allows the binding of these regions to a sialyl-di-Lewis a carbohydrate.
  • the structure for carrying the CDR3s of the invention will generally be of an antibody heavy or light chain sequence or substantial portion thereof in which the CDR3 regions are located at locations corresponding to the CDR3 region of naturally-occurring VH and VL antibody variable domains encoded by rearranged immunoglobulin genes.
  • the structures and locations of immunoglobulin variable domains may be determined by reference to http://www.imgt.org/.
  • amino acid sequence substantially as set out as residues 98-106 of Figure la and 2a may be carried as the CDR3 in a human heavy chain variable domain or a substantial portion thereof, and the amino acid sequence substantially as set out as residues and 95-103 of Figure lb and 2b may be carried as the CDR3 in a human light chain variable domain or a substantial portion thereof.
  • variable domains may be derived from any germline or rearranged human variable domain, or may be a synthetic variable domain based on consensus sequences of known human variable domains.
  • the CDR3 -derived sequences of the invention may be introduced into a repertoire of variable domains lacking CDR3 regions, using recombinant DNA technology.
  • 4 6 consist of from anything from 10 individual members upwards, for example from 10 to
  • Analogous shuffling or combinatorial techniques are also disclosed by Stemmer (1994) [39] who describes the technique in relation to a ⁇ -lactamase gene but observes that the approach may be used for the generation of antibodies.
  • a further alternative is to generate novel VH or VL regions carrying the CDR3 -derived sequences of the invention using random mutagenesis of, for example, the FG129 VH or VL genes to generate mutations within the entire variable domain.
  • Such a technique is described by Gram et al., (1992) [40], who used error-prone PCR.
  • Another method which may be used is to direct mutagenesis to CDR regions of VH or VL genes. Such techniques are disclosed by Barbas et al., (1994) [41] and Schier et al, (1996) [42].
  • a substantial portion of an immunoglobulin variable domain will generally comprise at least the three CDR regions, together with their intervening framework regions.
  • the portion may also include at least about 50% of either or both of the first and fourth framework regions, the 50% being the C-terminal 50% of the first framework region and the N-terminal 50% of the fourth framework region. Additional residues at the N- terminal or C-terminal end of the substantial part of the variable domain may be those not normally associated with naturally occurring variable domain regions.
  • construction of specific binding members of the present invention made by recombinant DNA techniques may result in the introduction of N- or C-terminal residues encoded by linkers introduced to facilitate cloning or other manipulation steps, including the introduction of linkers to join variable domains of the invention to further protein sequences including immunoglobulin heavy chains, other variable domains (for example in the production of diabodies) or protein labels as discussed in more detail below.
  • One embodiment of the invention provides specific binding members comprising a pair of binding domains based on the amino acid sequences for the VL and VH regions substantially as set out in Figures 1, i.e. amino acids 1 to 117 (VH) of Figure la and 2a and amino acids 1 to 114 (VL) of Figure lb and 2b.
  • Single binding domains based on either of these sequences form further aspects of the invention.
  • binding domains based on the amino acid sequence for the VH region substantially set out in Figure la and 2a such binding domains may be used as targeting agents since it is known that immunoglobulin VH domains are capable of binding target antigens in a specific manner.
  • these domains may be used to screen for complementary domains capable of forming a two-domain specific binding member which has in vivo properties as good as or equal to the FG88 antibodies disclosed herein.
  • phage display screening methods using the so-called hierarchical dual combinatorial approach as disclosed in WO92/01047 in which an individual colony containing either an H or L chain clone is used to infect a complete library of clones encoding the other chain (L or H) and the resulting two-chain specific binding member is selected in accordance with phage display techniques such as those described in that reference. This technique is also disclosed in Marks et al., [38].
  • Specific binding members of the present invention may further comprise antibody constant regions or parts thereof.
  • specific binding members based on the VL region shown in Figure lb and 2b may be attached at their C-terminal end to antibody light chain constant domains including human CK or Ck chains.
  • 5 specific binding members based on VH region shown in Figure b and 2b may be attached at their C- terminal end to all or part of an immunoglobulin heavy chain derived from any antibody isotype, e.g., IgG, IgA, IgE and IgM and any of the isotype sub- classes, particularly IgGl, IgG2 and IgG4.
  • the binding member is an scFv comprising, in the following order 1) a leader sequence, 2) a heavy chain variable region, 3) 3x GGGGS spacer, 4) a light chain variable region, and 5) poly- Ala and a 6x His tag for purification.
  • the binding member is an scFv comprising, in the following order 1) a leader sequence, 2) a light chain variable region, 3) 3x GGGGS spacer, and 4) a heavy chain variable region, optionally further comprising either 5' or 3' purification tags.
  • the binding member is provided in the form of a chimeric antigen receptor (CAR).
  • CARs may also be known as artificial T cell receptors, chimeric T cell receptors, or chimeric immunoreceptors.
  • the binding member is an scFv provided in the form of a chimeric antigen receptor (CAR)
  • it may be provided in either the heavy chain-light chain orientation or the light chain-heavy chain orientation.
  • Specific binding members of the present invention can be used in methods of diagnosis and treatment of tumours in human or animal subjects.
  • specific binding members of the invention may be labelled with a detectable label, for example a
  • radiolabel such as I or Tc
  • Labels also include enzyme labels such as horseradish peroxidase.
  • Labels further include chemical moieties such as biotin which may be detected via binding to a specific cognate detectable moiety, e.g., labelled avidin.
  • binding members of the invention may additionally be labelled with a functional label.
  • Functional labels include substances which are designed to be targeted to the site of cancer to cause destruction thereof.
  • Such functional labels include toxins such as ricin and enzymes such as bacterial carboxypeptidase or nitroreductase, which are capable of converting prodrugs into active drugs.
  • the specific binding members may be attached or otherwise associated with chemotherapeutic or cytotoxic agents, such as maytansines (DM1 and DM4), onides, auristatins, calicheamicin, duocamycin, doxorubicin
  • radiolabels such as Y or I.
  • the specific binding members of the present invention may be administered alone or in combination with other treatments, either simultaneously or sequentially, dependent upon the condition to be treated.
  • the present invention further provides products containing a specific binding member of the present invention and an active agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a tumour.
  • Active agents may include chemotherapeutic or cytotoxic agents including, 5-Fluorouracil, cisplatin, Mitomycin C, oxaliplatin and tamoxifen, which may operate synergist cally with the binding members of the present invention.
  • Other active agents may include suitable doses of pain relief drugs such as non-steroidal anti-inflammatory drugs (e.g., aspirin, paracetamol, ibuprofen or ketoprofen) or opitates such as morphine, or antiemetics.
  • pain relief drugs such as non-steroidal anti-inflammatory drugs (e.g., aspirin, paracetamol, ibuprofen or ketoprofen) or opitates such as morphine, or antiemetics.
  • non-steroidal anti-inflammatory drugs e.g., aspirin, paracetamol, ibuprofen or ketoprofen
  • opitates such as morphine, or antiemetics
  • Specific binding members of the present invention will usually be administered in the form of a pharmaceutical composition, which may comprise at least one component in addition to the specific binding member.
  • the pharmaceutical composition may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, diluent, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • a pharmaceutically acceptable excipient diluent, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g., intravenous.
  • injections will be the primary route for therapeutic administration of the compositions although delivery through a catheter or other surgical tubing is also used.
  • Some suitable routes of administration include intravenous, subcutaneous, intraperitoneal and intramuscular administration.
  • Liquid formulations may be utilised after reconstitution from powder formulations.
  • the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
  • Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
  • compositions for oral administration may be in tablet, capsule, powder or liquid form.
  • a tablet may comprise a solid carrier such as gelatin or an adjuvant.
  • Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
  • the formulation is a liquid it may be, for example, a physiologic salt solution containing non-phosphate buffer at pH 6.8-7.6, or a lyophilised powder.
  • the composition may also be administered via microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in certain tissues including blood.
  • sustained release carriers include semipermeable polymer matrices in the form of shared articles, e.g., suppositories or microcapsules.
  • Implantable or microcapsular sustained release matrices include polylactides (US Patent No. 3, 773, 919; EP-A-0058481) copolymers of L-glutamic acid and gamma ethyl-L-glutamate [43], poly (2-hydroxyethyl-methacrylate).
  • Liposomes containing the polypeptides are prepared by well-known methods: DE 3,218, 121A; Epstein et al, PNAS USA, 82: 3688-3692, 1985; Hwang et al, PNAS USA, 77: 4030-4034, 1980; EP-A-0052522; EP-A-0036676; EP-A-0088046; EP-A- 0143949; EP-A-0142541; JP-A-83-11808; US Patent Nos 4,485,045 and 4,544,545. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal rate of the polypeptide leakage.
  • compositions may be administered in a localised manner to a tumour site or other desired site or may be delivered in a manner in which it targets tumour or other cells.
  • the compositions are preferably administered to an individual in a "therapeutically effective amount", this being sufficient to show benefit to the individual.
  • the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g., decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.
  • compositions of the invention are particularly relevant to the treatment of existing tumours, especially cancer, and in the prevention of the recurrence of such conditions after initial treatment or surgery.
  • Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16 th edition, Oslo, A. (ed), 1980 [45].
  • the optimal dose can be determined by physicians based on a number of parameters including, for example, age, sex, weight, severity of the condition being treated, the active ingredient being administered and the route of administration.
  • a serum concentration of polypeptides and antibodies that permits saturation of receptors is desirable.
  • a concentration in excess of approximately O. lnM is normally sufficient.
  • a dose of 100mg/m 2 of antibody provides a serum concentration of approximately 20nM for approximately eight days.
  • doses of antibodies may be given weekly in amounts of 10- 300mg/m 2 .
  • Equivalent doses of antibody fragments should be used at more frequent intervals in order to maintain a serum level in excess of the concentration that permits saturation of the LecLe x carbohydrate.
  • the dose of the composition will be dependent upon the properties of the binding member, e.g., its binding activity and in vivo plasma half-life, the concentration of the polypeptide in the formulation, the administration route, the site and rate of dosage, the clinical tolerance of the patient involved, the pathological condition afflicting the patient and the like, as is well within the skill of the physician.
  • doses of 300Dg of antibody per patient per administration are preferred, although dosages may range from about lC ⁇ g to 6 mg per dose. Different dosages are utilised during a series of sequential inoculations; the practitioner may administer an initial inoculation and then boost with relatively smaller doses of antibody.
  • This invention is also directed to optimise immunisation schedules for enhancing a protective immune response against cancer.
  • the binding members of the present invention may be generated wholly or partly by chemical synthesis.
  • the binding members can be readily prepared according to well- established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, (1984) [46], in M. Bodanzsky and A.
  • Another convenient way of producing a binding member according to the present invention is to express the nucleic acid encoding it, by use of nucleic acid in an expression system.
  • the present invention further provides an isolated nucleic acid encoding a specific binding member of the present invention.
  • Nucleic acid includes DNA and RNA.
  • the present invention provides a nucleic acid which codes for a specific binding member of the invention as defined above. Examples of such nucleic acid are shown in Figuresl and 2. The skilled person will be able to determine substitutions, deletions and/or additions to such nucleic acids which will still provide a specific binding member of the present invention.
  • the present invention also provides constructs in the form of plasmids, vectors, transcription or expression cassettes which comprise at least one nucleic acid as described above.
  • the present invention also provides a recombinant host cell which comprises one or more constructs as above.
  • a nucleic acid encoding a specific binding member of the invention forms an aspect of the present invention, as does a method of production of the specific binding member which method comprises expression from encoding nucleic acid therefor. Expression may conveniently be achieved by culturing under appropriate conditions recombinant host cells containing the nucleic acid. Following production by expression, a specific binding member may be isolated and/or purified using any suitable technique, then used as appropriate.
  • Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems.
  • Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, NSO mouse melanoma cells and many others.
  • a common, preferred bacterial host is E. coli.
  • the expression of antibodies and antibody fragments in prokaryotic cells such as E. coli is well established in the art. For a review, see for example Pliickthun (1991) [48]. Expression in eukaryotic cells in culture is alsoavailable to those skilled in the art as an option for production of a specific binding member, see for recent review, for example Reff (1993) [49]; Trill et al, (1995) [50].
  • Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
  • Vectors may be plasmids, viral e.g., 'phage, or phagemid, as appropriate.
  • plasmids viral e.g., 'phage, or phagemid, as appropriate.
  • Many known techniques and protocols for manipulation of nucleic acid for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Ausubel et al. , (1992)[52].
  • a further aspect of the present invention provides a host cell containing nucleic acid as disclosed herein.
  • a still further aspect provides a method comprising introducing such nucleic acid into a host cell.
  • the introduction may employ any available technique.
  • suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g., vaccinia or, for insect cells, baculovirus.
  • suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage.
  • the introduction may be followed by causing or allowing expression from the nucleic acid, e.g., by culturing host cells under conditions for expression of the gene.
  • the nucleic acid of the invention is integrated into the genome ⁇ e.g., chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.
  • a binding member which competes for binding to the same epitope as a binding member according to the invention.
  • the competing binding member is in the same format as the binding member according to the invention described herein, but with different CDR or variable region sequences.
  • the present invention also provides a method which comprises using a construct as stated above in an expression system in order to express a specific binding member or polypeptide as above. Preferred features of each aspect of the invention are as for each of the other aspects mutatis mutandis.
  • the prior art documents mentioned herein are incorporated to the fullest extent permitted by law. BRIEF DESCRIPTION OF THE DRAWINGS
  • Figure la Amino acid and nucleotide sequence for the mouse IgGl heavy chain of the FG129 mAb. Numbers refer to the standardised IMGT system for the numbering of antibody sequences [59].
  • Figure lb Amino acid and nucleotide sequence for the mouse kappa chain of the FG129 mAb. Numbers refer to the standardised IMGT system for the numbering of antibody sequences [59].
  • Figure 2 The chimeric version of the FG129 mAb (original murine variable regions linked to human constant region sequence), produced by a transfected cell line, binds the target cell line (HCT-15).
  • Figure 2a Amino acid and nucleotide sequence for the human IgGl heavy chain of the FG129 mAb. Numbers refer to the standardised IMGT system for the numbering of antibody sequences [59].
  • Figure 2b Amino acid and nucleotide sequence for the human kappa chain of the FG129 mAb. Numbers refer to the standardised IMGT system for the numbering of antibody sequences [59].
  • Figure 3a ELISA screening of FG129 to over 600 glycans arrayed on a glass slide by the CFG.
  • Square represents glucosylamine
  • circle represents galactose
  • triangle represents fucose
  • diamond represents sialic acid.
  • Figure 3b Indirect Western blot analysis of the antigens recognised by mAb FG129 and mAb ch 129 (1 ⁇ g/ml).
  • Lane M molecular marker (in red); Lane 1 : Colo205 cell lysates (lxlO 5 cells); Lane 2: Colo205 TGL (lxlO 6 cells); Lane 3 : HCT-15 cell lysates (lxlO 5 cells); Lane 4: HCT-15 TGL (lxlO 6 cells); Lane 5: BxPc3 cell lysates (lxlO 5 cells); Lane 6: BxPc3 TGL (lxlO 6 cells); Lane 7: LS180 cell lysates (lxlO 5 cells); Lane 8: LS180 TGL (lxlO 6 cells).
  • Negative control consisted of omission of primary antibody.
  • CA19.9 was used as positive control recognising sialyl-Lewis a on glycolipids as well as glycoproteins.
  • Figure 4 ELISA analysis of FG129 and CH129 binding to sialyl-Lewis a -HSA.
  • CA19.9 was used as positive control recognising sialyl-Lewis a on glycolipids as well as glycoproteins.
  • Negative controls consisted of an isotype antibody that does not recognise sialyl-Lewis a , HSA coated wells, uncoated wells where the antigen was omitted, and wells where FG129 was omitted. Error bars represent the mean ⁇ SD of duplicate wells.
  • Figure 5a Binding of FG129 ( ⁇ g/ml) by IHC to colorectal, pancreatic, gastric, ovarian and lung TMAs. Representative images of different staining levels are shown i) negative, ii) weak, iii) moderate and iv) strong (magnification x20).
  • Figure 5b Kaplan-Meier analysis of disease-free survival of pancreatic patients staining with FG129 mAb. Cut-off for high versus low was determined by X-tile.
  • Figure 5c Normal human tissue (AMSBIO) binding of FG129, showing very limited binding in 1) Gallbladder; 2) Ileum; 3) Liver; 4) Oesophagus; 5) Pancreas; 6)Thyroid (magnification x20).
  • AMSBIO Normal human tissue binding of FG129, showing very limited binding in 1) Gallbladder; 2) Ileum; 3) Liver; 4) Oesophagus; 5) Pancreas; 6)Thyroid (magnification x20).
  • Figure 6a Indirect immunofluorescence staining and flow cytometric analysis of FG129 and CH129 ⁇ g/ml) mAb binding to the cell surface of tumour cell lines.
  • Figure 6b Indirect immunofluorescence staining and flow cytometric analysis of FG129 ⁇ g/ml) mAb binding to the cell surface of HUVEC normal umbilical cells. An anti-CD55 mAb was used as a positive control and an anti-IgG isotype antibody as a negative control.
  • Figure 6c Indirect immunofluorescence staining and flow cytometric analysis of FG129 and chl29 ⁇ g/ml) mAbs binding to whole blood. An anti-HLA mAb w6/32 was used as a positive control and an anti-IgG isotype antibody as a negative control.
  • Figure 7 Indirect immunofluorescence staining and flow cytometric analysis of titrations of FG129 mAb and CH129 mAb binding to the cell surface of Colo205 (7a), HCT-15 (7b), BxPc3 (7c) and LSI 80 (7d) cells.
  • Figure 8 ADCC killing of Colo205 (8a) and HCT-15 (8b) by FG129 and CH129. Erbitux was used as positive control, while PBMCs and cells alone were used as negative controls. Anova test performed using GraphPad Prism6 shows the significant difference between each concentration and the negative control consisting of cells with PBMCs only.
  • Figure 9 CDC killing of Colo205 by FG129 and CH129. Erbitux was used as positive control, while PBMCs and cells alone were used as negative controls. Anova test performed using GraphPad Prism6 shows the significant difference between each concentration and the negative control consisting of cells with PBMCs only.
  • Figure 10 Z-stack confocal microscopy of Alexa Fluor® 488 (green) labelled FG129 (panel 10a) and CH129 (panel 10b) internalising in live Colo205, BxPC3 and HCT-15 showing co- localisation with lysosomes.
  • the plasma membrane was labelled with CellMaskTM Orange (red/C), the lysosomes with LysoTracker® Deep Red (purple/D) and the nucleus with Hoechst 33258 (blue/ A) (magnification x60).
  • FIG 11a Cytotoxicity of Fab-ZAP-FG129 in antigen positive (HCT15, Colo205, BxPC3, ASPC1) and negative (LoVo, LSI 80) cancer cell lines.
  • HCT15, Colo205, BxPC3, ASPC1 and negative (LoVo, LSI 80) cancer cell lines The cytotoxicity of internalised FG129 pre-incubated with saporin-linked anti-mouse IgG Fab fragment was evaluated using 3 H-thymidine incorporation. Results are presented as percentage of proliferation of cells treated with the primary mAb only. Error bars show the mean ⁇ SD from four independent experiments.
  • Figure lib Fab-ZAP-IgG Isotype internalisation assay. Results are presented normalised, as percentage of proliferation of cells treated with the primary mAb only. Error bars show the mean ⁇ SD from three independent experiments.
  • Figure 11c Cytotoxicity of Fab-ZAP-CH129 against HCT15, Colo205, BxPC3cancer cell lines.
  • the cytotoxicity of internalised CH129 pre-incubated with saporin-linked anti-human IgG Fab fragment was evaluated using 3 H-thymidine incorporation. Results are presented normalised, as percentage of proliferation of cells treated with the primary mAb only. Error bars show the mean ⁇ SD from four independent experiments.
  • Figure lid Fab-ZAP-IgG Isotype internalisation assay. Results are presented normalised, as percentage of proliferation of cells treated with the primary mAb only. Error bars show the mean ⁇ SD from three independent experiments.
  • Figure llf WST8 cytotoxicity assay showing in vitro efficacy of CH129-ADC constructs on HCT-15. CH129 constructs show 50-60% cell killing. Rituximab-ADC constructs were used as controls for specific killing. Ritux-vcE and Ritux-DMl do not show cell killing. Ritux- DM4 shows similar killing activity to the CHI 29 constructs, indicating non-specific cell killing.
  • Figure llg WST8 cytotoxicity assay showing bystander killing of the CH129-vcE construct.
  • Figure llh WST8 cytotoxicity assay showing bystander killing of the CH129-DM4 construct.
  • Figure Hi WST8 cytotoxicity assay showing bystander killing of the CH129-DM1 construct.
  • Figure 12a Sandwich ELISA using FG129 for the detection of secreted sialyl-Lewis a in sera from pancreatic cancer patients. Negative controls consisted of a normal serum sample from a healthy donor, and 2%BSA-PBS alone. Sialyl-Lewis a -HSA was used as a positive control.
  • Figure 12b Competition FACS assay showing binding to HCT-15 cell line of pre-incubated FG129 with sera from patients from the pancreatic TMA cohort. Positive controls consisted of normal sera samples from five healthy donors (shown as average between the five), and 2%BSA-PBS pre-incubated with FG129. Negative controls consisted of sialyl-Lewis a -HSA pre-incubated with FG129 and 2%BSA-PBS alone.
  • Figure 13a Sequence of FG129-scFv, comprised of 1) leader sequence, 2) heavy chain variable region, 3) 3x GGGGS spacer, 4) light chain variable region, 5) poly-Ala and 6x His tag for purification.
  • Figure 13b ELISA analysis of FG129-scFv and CH129 binding to sialyl-Lewis a -HSA. Error bars represent the mean ⁇ SD of duplicate wells.
  • Figure 13c Indirect immunofluorescence staining and flow cytometric analysis of titrations of FG129-scFv binding to the cell surface of Colo205. DETAILED DESCRIPTION OF THE INVENTION
  • Binding to tumour cell lines 1 x 10 cancer cells were incubated with 50 ⁇ 1 of primary antibodies at 4°C for 1 hr. Cells were washed with 200 ⁇ 1 of RPMI 10% new born calf serum (NBCS: Sigma, Poole, UK) and spun at l,000rpm for 5 min. Supernatant was discarded and 50 ⁇ 1 of FITC conjugated anti-mouse IgG Fc specific mab (Sigma; 1/100 in RPMI 10%) NBCS) was used as secondary antibody. Cells were incubated at 4°C in dark for 1 hr then washed with 200 ⁇ 1 RPMI 10% NBCS and spun at l,000rpm for 5 min.
  • Binding to blood 50 ⁇ 1 of healthy donor blood was incubated with 50 ⁇ 1 primary antibody at 4°C for lhr. The blood was washed with 150 ⁇ 1 of RPMI 10% NBCS and spun at l,000rpm for 5min. Supernatant was discarded and 50 ⁇ 1 FITC conjugated anti-mouse IgG Fc specific mAb (1/100 in RPMI 10% NBCS) was used as the secondary antibody. Cells were incubated at 4°C in the dark for lhr then washed with 150 ⁇ 1 RPMI 10% NBCS and spun at l,000rpm for 5min.
  • Colo205 cell pellet (5 x 10 cells) was resuspended in 500 ⁇ 1 of Mannitol/HEPES buffer (50mM Mannitol, 5mM HEPES, pH7.2, both Sigma) and passed through 3 needles (23G, 25G, 27G) each with 30 pulses. 5 ⁇ 1 of 1M CaCl2 was added to the cells and passed through 3 needles each with 30 pulses as above. Sheared cells were incubated on ice for 20 min then spun at 3,000g- for 15 min at room temperature. Supernatant was collected and spun at 48,000g- for 30 min at 4°C and the supernatant was discarded.
  • Mannitol/HEPES buffer 50mM Mannitol, 5mM HEPES, pH7.2, both Sigma
  • the pellet was resuspended in 1ml methanol followed by 1ml chloroform and incubated with rolling for 30 min at room temperature. The sample was then spun at l,200g- for 10 min to remove precipitated protein. The supernatant, containing plasma membrane glycolipids, was collected and stored at -20°C.
  • FG129, CH129 and scFvl29 mAbs diluted in HBS-P buffer (10 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 0.005% (v/v) surfactant P20) were run across the chip at a flow rate of 50 ⁇ /min and BIAevaluation software 4.1 was used to determine the kinetic binding parameters from which affinities are calculated.
  • ELISA plates were coated overnight at 4°C with 100 ng/well Lewis-HSA antigens (Isosep), blocked with PBS/BSA and incubated with primary mAbs (direct ELISA). Antibody or Lewis antigen binding was detected using biotinylated secondary mAb (Sigma). Plates were read at 450 nm by Tecan Infinite F50 after incubation with Streptavidin Horseradish Peroxidase (HRPO) conjugate (Invitrogen).
  • HRPO Streptavidin Horseradish Peroxidase
  • SDS-PAGE and Western blot analysis Briefly, 1x10 5 or 10 6 cell equivalents of Colo205 cell lysate, plasma membrane, total lipid extract, plasma membrane lipid extract or HCT-15 cell ly sates were analysed for FG129 binding.
  • Tumour cell total and plasma membrane lipid extracts and cell lysates were reduced with dithiothreitol (DTT; Pierce Biotechnology, ThermoFisher, Loughborough, UK) and subjected to SDS-PAGE using NOVEX 4% to 12% Bis-Tris gels (Invitrogen), and transferred to Immobilon-FL PVDF membrane (Merck Millipore, Watford, UK) using lx transfer buffer (2 Ox, Invitrogen) and 20% (v/v) methanol at 30V for lhr.
  • DTT dithiothreitol
  • NOVEX 4% to 12% Bis-Tris gels
  • Immobilon-FL PVDF membrane Merck Millipore, Watford, UK
  • lx transfer buffer (2 Ox, Invitrogen
  • 20% (v/v) methanol at 30V for lhr.
  • Membranes were blocked with 5% (w/v) non-fat dry milk in 0.05%) (v/v) Tween-PBS for lhr then probed with primary antibodies diluted in Tween- PBS, 2% BSA for lhr. Primary antibody binding was detected using biotin-conjugated anti-mouse IgG Fc specific secondary antibody (Sigma; 1/2000 dilution in Tween-PBS, 2% BSA) for lhr, and visualized using IRDye 800CW streptavidin (LICOR Biosciences, UK; 1/1000 in Tween-PBS 2% BSA).
  • RNA source and total RNA preparation Approximately 5x10 cells from hybridomasFG129 were taken from tissue culture, washed once in PBS, and the cell pellet treated with 500 ⁇ 1 Trizol (Invitrogen). After the cells had been dispersed in the reagent, they were stored at - 80°C until RNA was prepared following manufacturer's protocol. RNA concentration and purity were determined by Nanodrop. Prior to cDNA synthesis, RNA was DNase I treated to remove genomic DNA contamination (DNase I recombinant, RNase-free, Roche Diagnostics, Burgess Hill, UK) following manufacturer's recommendations.
  • First-strand cDNA was prepared from 3 ⁇ g of total RNA using a first- strand cDNA synthesis kit and AMV reverse transcriptase following manufacturer's protocol (Roche Diagnostics). After cDNA synthesis, reverse transcriptase activity was assessed for ase activity.
  • GAPDH PCR to assess cDNA quality A PCR was used to assess cDNA quality; primers specific for the mouse GAPDH house-keeping gene (5'- TT AGC ACCCCTGGCC AAGG-3 ' and 5'-CTTACTCCCTTGGAGGCCATG-3') were used with a hot-start Taq polymerase (AmpliTaq Gold 360, Invitrogen) for 35 cycles (95°C, 3mins followed by 35 cycles of 94°C/30secs, 55°C/30secs, 72°C/lmin; final polishing step of lOmins at 72°C). Amplified products were assessed by agarose gel electrophoresis.
  • PCR primer design for cloning FG129 variable regions Primers were designed to amplify the heavy and light chain variable regions based upon the PCR product sequence data. Primers were designed to allow cloning of the relevant chain into unique restriction enzyme sites in the hlgGl/kappa double expression vector pDCOrig-hlgGl . Each 5' primer was targeted to the starting codon and leader peptide of the defined variable region, with a Kozak consensus immediately 5' of the starting codon. Each 3' primer was designed to be complementary to the joining region of the antibody sequence, to maintain reading frame after cloning of the chain, and to preserve the amino acid sequence usually found at the joining region/constant region junction.
  • PCR amplification was carried out with 12 mouse VH region-specific 5' primers and 3 ' primers specific for previously determined antibody subclass with a hot-start Taq polymerase for 35 cycles (94°C, 5min followed by 35 cycles of 94°C/lmin, 60°C/lmin, 72°C/2min; final polishing step of 20min at 72°C). Amplified products were assessed by agarose gel electrophoresis. Positive amplifications resulted for the VH4 primer.
  • PCR amplification was carried out with mouse VK region-specific 5' and 3' mouse CK specific primers with a hot-start Taq polymerase for 35 cycles (94°C, 5mins followed by 35 cycles of 94°C/lmin, 60°C/lmin, 72°C/2mins; final polishing step of 20mins at 72°C). Amplification products were assessed by agarose gel electrophoresis. Positive amplifications resulted with the VKI and VK2 primers for FG129.
  • PCR product purification and sequencing PCR products were purified using a Qiaquick PCR purification kit (Qiagen, Crawley, UK). The concentration of the resulting DNA was determined by Nanodrop and the purity assessed by agarose gel electrophoresis. PCR products were sequenced using the originating 5 ' and 3 ' PCR primers at the University of Nottingham DNA sequencing facility
  • Cloning strategy The PCR product for cloning was generated using a proof-reading polymerase (Phusion, New England Biolab s) was cloned into a TA vector (pCR2.1; Invitrogen).
  • FG129 heavy/light chain PCR for cloning PCR amplification was carried out using a proof-reading polymerase (Phusion; NEB) and the cloning primers described above using the FG129 cDNA template previously described for 35 cycles (98°C, 3min followed by 35 cycles of 98°C/30sec, 58°C/30sec, 72°C/45sec; final polishing step of 3min at 72°C). Successful amplification was confirmed by agarose gel electrophoresis.
  • TOPO light chain cloning Amplified FG129 light chain was treated with Taq polymerase (NEB) for 15min at 72°C to add 'A' overhangs compatible with TA cloning. Treated PCR product was incubated with the TOPO TA vector pCR2.1(Invitrogen) and transformed into chemically competent TOP10F cells according to manufacturer's instructions. Transformed bacteria were spread on ampicillin (8C ⁇ g/ml) supplemented LB agar plates, which were then incubated overnight at 37°C. Colonies were grown in liquid culture (LB supplemented with 8C ⁇ g/ml ampicillin) and plasmid DNA prepared (spin miniprep kit, Qiagen).
  • Presence of an insert was confirmed by sequential digestion with BsiWI and BamHI and agarose gel electrophoresis. Sequencing was carried out on miniprep DNA from colonies using T7 and M13rev primers. The DNA insert from one such colony had the predicted FG129 light chain sequence; a 300ml bacterial LB/ampicillin culture was grown overnight and plasmid DNA prepared by maxiprep (plasmid maxi kit, Qiagen). Maxiprep DNA insert was confirmed by sequencing.
  • TOPO heavy chain cloning Amplified FG129 heavy chain was treated with Taq polymerase (NEB) for 15min at 72°C to add 'A' overhangs. Treated PCR product was incubated with the TOPO TA vector pCR2.1 and transformed into chemically competent TOP10F' cells as above. Transformed bacteria were spread on ampicillin supplemented LB agar plates which were then incubated overnight at 37°C. Colonies were grown in liquid culture (LB/ampicillin) and plasmid DNA prepared (spin miniprep kit). Presence of an insert was confirmed by digestion with Hindlll and Afel and agarose gel electrophoresis.
  • Sequencing was carried out on miniprep DNA from a number of colonies using T7 and M13rev primers.
  • the DNA insert from one such colony had the predicted FG129 heavy chain sequence; a 300ml bacterial LB/ampicillin culture was grown overnight and plasmid DNA prepared by maxiprep (plasmid maxi kit, Qiagen). Maxiprep DNA insert was confirmed by sequencing.
  • pDCOrig-hlgGl double expression vector light chain cloning The FG129 light chain was digested from the TOPO vector pCR2.1 by sequential digestion with BsiWI and BamHI and the 400bp insert DNA agarose gel purified using a QIAquick gel extraction kit (Qiagen) following manufacturer's recommendations.
  • This insert was ligated into previously prepared pDCOrig-hlgGl vector (see above) and transformed into chemically competent TOP10F' cells. Transformations were spread on 35 ⁇ g/ml Zeocin supplemented LB agar plates which were then incubated overnight at 37°C. Colonies were grown in liquid culture (LB supplemented with 35 ⁇ g/ml Zeocin) and plasmid DNA prepared (spin miniprep kit, Qiagen). Sequencing was carried out on miniprep DNA from all colonies using a sequencing primer sited in the human kappa constant region.
  • the DNA insert from one of the colonies had the predicted FG129 light chain sequence correctly inserted in pDCOrig-hlgGl; a 300ml bacterial LB/zeocin culture was grown overnight and plasmid DNA prepared by maxiprep (plasmid maxi kit, Qiagen).
  • pDCOrig-hlgGl double expression vector heavy chain cloning The FG129 heavy chain insert was digested from the TOPO vector pCR2.1 by digestion with Hindlll and Afel. Vector (pDCOrig-hIgGl-129k) containing the FG129 kappa light chain (prepared above) was also digested with Hindlll and Afel.
  • the vector DNA was then phosphatase treated according to manufacturer's recommendations (Antarctic Phosphatase, NEB). After agarose gel electrophoresis, the 6.5kb pDCOrig-hlgGl vector band and 400bp FG129H insert band were isolated using a QIAquick gel extraction kit (Qiagen) following manufacturer's recommendations. The insert was ligated into the pDCOrig-hlgGl vector and transformed into chemically competentTOPlOF' cells. Transformations were spread on 35 ⁇ g/ml Zeocin supplemented LB agar plates which were then incubated overnight at 37°C.
  • Colonies were grown in liquid culture (LB supplemented with 35 ⁇ g/ml Zeocin) and plasmid DNA prepared (spin miniprep kit, Qiagen). Presence of an insert was confirmed by digestion with Hindlll and Afel and agarose gel electrophoresis. Sequencing was carried out on miniprep DNA from a number of the colonies using a sequencing primer sited in the human IgGl constant region. The DNA insert from one of the colonies had the predicted FG129 heavy chain sequence correctly inserted in pDCOrig- hlgGl; a 300ml bacterial LB/zeocin culture was grown overnight and plasmid DNA prepared by maxiprep (plasmid maxi kit, Qiagen). Sequencing was used to confirm that both heavy and light chain loci.
  • antibodies can be purified from supernatant collected from transiently, or subsequently stable, transfected cells by protein A or protein G affinity chromatography based on standard protocols, for example Sambrook et al. [61]. Cloning, expression, purification and characterisation of the FG129-scFv
  • the heavy chain and light chain variable region were incorporated in silico into a single scFv sequence in the orientation; leader; heavy chain variable domain; spacer (3x GGGGS); light chain variable domain; spacer (6x Ala); purification tag (6x His) and synthesised.
  • Expi293 cells were transfected and allowed to produce protein transiently (6 days). His-tagged scFv was purified from Expi-293 supernatant using immobilised cobalt chromatography (HiTrap Talon 1ml columns; GE Healthcare).
  • a biotinilated anti-His tag antibody was used as a secondary antibody (6x- His Epitope Tag Antibody, Biotin conjugated, clone HIS.H8; Thermo Fisher).
  • Immunohistochemistry assessment for FG129 To determine the therapeutic value of FG129, it was screened on pancreatic, lung, gastric, ovarian, colorectal cancer tissue microarrays by immunohistochemistry (IHC).
  • Tissue sections were washed with PBS and incubated with preformed 1/50 (PBS) streptavidin- biotin/horseradish peroxidase complex (Dako Ltd) for 30min at room temperature. 3, 3'-Diaminobenzidine tetra hydrochloride (DAB) was used as a substrate. Each section was incubated twice with ⁇ of DAB solution for 5min. Finally, sections were lightly counterstained with haematoxylin (Sigma-Aldrich, Poole Dorset, UK) before dehydrating in graded alcohols, cleaning by immersing in xylene and mounting the slides with Distyrene, plasticiser, xylene (DPX) mountant (Sigma).
  • PBS preformed 1/50
  • DAB 3'-Diaminobenzidine tetra hydrochloride
  • the study populations include cohorts of a consecutive series of 462 archived colorectal cancer (29) specimens (1994 -2000; median follow up 42 months; censored December 2003; patients with lymph node positive disease routinely received adjuvant chemotherapy with 5-flurouracil/folinic acid), 350 ovarian cancer (28) samples (1982-1997; median follow up 192 months: censored November 2005 :patients with stage II to IV disease received standard adjuvant chemotherapy which in later years was platinum based ), 142 gastric cancer (26) samples (2001-2006; median follow up 66months; censored Jan 2009; no chemotherapy) 68 pancreatic and 120 biliaiy/ampullary cancer (27) samples (1993-2010:median 45 months; censored 2012; 25-46% of patients received adjuvant chemotherapy with 5-fluorouracil/folinic acid and gemcitabine) 220 non small cell lung cancers (01/1996-07/2006: median follow up 36 months censored May 2013; none of the patients received chemotherapy prior
  • ADCC and CDC Cells (5 ⁇ 10 3 ) were co-incubated with ⁇ of PBMCs, 10% autologous serum or media alone or with mAbs at a range of concentrations. Spontaneous and maximum releases were evaluated by incubating the labeled cells with medium alone or with 10% Triton X-100, respectively. After 4hr of incubation, 50 ⁇ 1 of supernatant from each well was transferred to 96 well lumaplates. Plates were allow to dry overnight and counted on a Topcount XT counter (Perkin Elmer, Cambridge, UK). The mean percentage lysis of target cells was calculated according to the following formula:
  • ADC was evaluated by measuring the cytotoxicity of immune-complexed mAbs with a mouse Fab-ZAP secondary conjugate (Advanced Targeting Systems) (30). Cells were plated in triplicates overnight into 96-well plates (2,000 cells, 90 ⁇ /well). After preincubaton (30 minutes at room temperature) of a concentration range of FG129 or CHI 29 mAbs with 50 ng of the Fab-ZAP conjugate, 10 ⁇ of conjugate or free mAb was added to the wells and incubated for 72 hours. Control wells, consisted of cells incubated without conjugate, incubated with secondary Fab-ZAP without primary mAb and incubated with a control mAb in the presence of Fab-ZAP. Cell viability was measured by 3 H-thymidine incorporation during the final 24 hours. Results are expressed as a percentage of 3 H-thymidine incorporation by cells incubated with conjugate compared with primary mAb only.
  • CH129 constructs were produced by ADC Biotechnology: one with the auristatin MMAE linked via a cleavable dipeptide valine- citruline linker and a para-aminobenzylalcohol (PABA) self-immolative spacer, one with the DM4 maytansinoid linked via the intermediately cleavable hindered disulphide linker SPDB and one with the DM1 maytansinoid linked through the non-cleavable SMCC linker.
  • PABA para-aminobenzylalcohol
  • the cytotoxic effect of the CH129-ADC constructs was assessed by using the water-soluble tetrazolium salt WST-8 (Sigma) to measure the activity of hydrogenases which is directly proportional with the number of viable cells.
  • Cells were plated in 96-well plates at a density of 2000 cells/9( ⁇ l/well in 10%FBS-RPMI with Penicillin-Streptomycin (Sigma) and incubated overnight at 37°C, 5%C02.
  • the ADC constructs were then added to the cells at different concentrations in a final volume of ⁇ /well and the plates were incubated at 37°C, 5%C02 for 72h with the antibody constructs.
  • the WST-8 was then added ( ⁇ /well) and the plates were further incubated 37°C, 5%C02 for 3h. After the 3h incubation, the plates were read at 450 nm by Tecan Infinite F50. Results are expressed as percentages of control wells, consisting of cells only without any antibody. Cytotoxicity was studied on two colorectal cell lines Colo205 and HCT-15 that express high cell surface densities of the targeted antigen sialyl-lewis-a.
  • FG129 was produced by immunising Balb/c mice with plasma membrane lipid extracts from LSI 80 cells (colorectal cell line) incorporated into liposomes, at two-week intervals over a period of 2 months, alpha-galactosylceramide was used as an adjuvant in the first, third and fourth immunisation and anti-CD40 mAb used during the second immunisation.
  • LSI 80 cells colonal cell line
  • alpha-galactosylceramide was used as an adjuvant in the first, third and fourth immunisation and anti-CD40 mAb used during the second immunisation.
  • Analysis of antibody response to immunisations Antibody titres were initially monitored by lipid enzyme-linked immunosorbent assay (ELISA). Flow cytometry analysis (FACS) was also carried out using LS I 80 tumour cells and Western blot using LS180.
  • hybridoma was considered a clone.
  • Methods for clonal expansion, bulk culture and antibody purification of antibodies or antibody fragments are available using conventional techniques known to those skilled in the art.
  • chimeric antibody is intended to refer to antibodies in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as an antibody in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody.
  • Chimeric (or humanised) antibodies of the present invention can be prepared based on the sequence of a murine mAb prepared as described above.
  • the amino acid and nucleotide sequence for the variable and constant regions of the heavy ( Figure la) and light chains (Figure lb) of the FG129 mAb are shown in Figures 1. Numbers refer to the standardised IMGT system for the numbering of antibody sequences [49].
  • the CDR1, CDR 2 and CDR 3 regions are indicated.
  • the FG129 heavy chain belongs to the mouse heavy chain family IGHV10-1 *02 (IGHD1-1 *01, IGHJ4*01), with three mutations compared to the parental germline gene.
  • the FG129 light chain belongs to the mouse kappa chain family IGKV8-19*01 (IGKJ4*01), with two mutations compared to the parental germline gene.
  • FG129 heavy and light chain variable regions were cloned into a human IgGl expression vector. This was transfected into CHO-S or FEK293 cells and human antibody purified on protein G. The chimeric mAbs CH129 bound to the colorectal cell line, Colo205. The amino acid and nucleotide sequence for the heavy and light chains of the human chl29 mAb are shown in Figures 2a and 2b respectively.
  • MAb FG129 is a mouse IgGlk isotype that was generated by immunising Balb/c mice with glycolipid extracts from colorectal cell line LSI 80. Glycan profiling analysis done by CFG on >600 natural and synthetic glycans shows a high specificity of FG129 binding sialyl-di- Lewis a (100%) and sialyl-Lewis a"x (89%).
  • FG129 binding was assessed by Western blotting (figure 3b).
  • Tumour lysates or tumour glycolipid extracts from colorectal (Colo205 HCT-15 and LSI 80) and pancreatic cells lines (BxPc3) were blotted with FG129, CH129 mAb, secondary antibody alone or CA19.9 (anti- sialyl lewis a Mab).
  • FG129 and CH129 bound to a wide range of glycoproteins in Colo205 and HCT-15 lysate and to a smaller number of glycoproteins in BxPc3 and LSI 80 ly states.
  • FG129 failed to bind to any of the tumour glycolipid extracts.
  • CA19.9 showed binding to a wider range of glycoproteins in BxPc3, Colo205 and LSI 80 and to glycolipids from BxPc3 and HCT-15 cells. These results suggest that FG129 prefers to bind to six carbohydrate residues and prefers sialyl-di-Lewis a which is predominantly expressed on proteins.
  • CA19.9 which prefers the 3 carbohydrate residue glycan, sialyl-Lewis a , binds to both lipids and proteins.
  • the affinity measurements revealed subnanomolar functional affinity for FG129 and nanomolar affinity for CH129 , both showing relatively fast on-rates and slow off-rates for sialyl-Lewis-a binding (Table lb).
  • the monovalent binding affinity of the scFvl29 was lower (10 "7 M), with a slower on-rate but similar off-rate, suggesting bivalent binding on the chip by FG129 and CH129.
  • FG129 To determine the therapeutic value of FG129, it was screened on colorectal, gastric, pancreatic, lung, an d ovarian tumour tissue microarrays (TMAs) by immunohistochemistry (IHC). The tumour tissue binding of FG129 was assessed by IHC on tumour TMAs. The mAb bound to 74% (135/182) of pancreatic tumours, 50% (46/92) of gastric tumours, 36%> (100/281) of colorectal tumours, 27% (89/327) of ovarian and 21% (42/201) of NSCLC tumours (Table 1). Table 2.
  • IVbcferale 10 11 25 9 61 34 21 6 9 4
  • Fig. 5a Representatives of different staining levels of tumour tissues with FG129 are shown in Fig. 5a.
  • FG129 In normal tissue, FG129 had a very restricted binding pattern and did not bind most normal tissues like heart, brain, stomach, and kidney (table 1) . Very limited binding was seen in gallbladder (weak), ileum (1%), liver (1%), oesophagus (5%), pancreas (10%), and thyroid (weak: (Fig. 5c). This is in direct contrast to CA19.9 mAb which recognizes sialyl Lewis a on both lipids and proteins. It binds strongly (3+) to oesophagus, gallbladder and liver, moderately (2+) to breast and weakly (1+) to rectum. FG129 displays strong tumour tissue binding with low normal tissue reactivity, and is associated with poor prognosis in pancreatic cancer patients.
  • Table 3 Summary of FG129 and CA19.9 binding to a panel of normal tissues using paraffin-fixed sections. Intensity of staining is shown as 0, 1, 2 or 3, relating to negative, weak, moderate or strong binding.
  • CH129 had a very restricted binding pattern and did not bind most normal tissues like heart, brain, stomach, and kidney (table 1). Very limited binding was seen in gallbladder (weak), ileum (1%), liver (1%), oesophagus (5%), pancreas (10%), and thyroid (weak: (Fig. 5a).
  • FG129 and CHI 29 showed strong binding (geometric mean (Gm) >1000) to tumour cell lines HCT-15, Colo205, moderate binding (Gm -100) to BxPc3, ASPC1, LS180, DLD1, and DMS79 and no binding to AGS, SW480, EKVX, MCF-7, LoVo, DU4475, OVCAR3, OVCAR4 and OVCA433.
  • HCT-15, Colo205, ASPC1, BxPc3, LS180, DLD1, and DMS79 would be good models for assessing the sensitivity of tumour cells with different cell densities of sialyl-Lewis a to FG129 therapy (Figure 6a).
  • FG129 failed to bind to normal HUVEC cells ( Figure 6b).
  • an anti-CD55 mAb was used as a positive control and an anti-IgG isotype antibody as a negative control.
  • FG129 and CH129 did not bind to PBMCs from a range of healthy donors (Figure 6c).
  • SABC antigen density
  • FG129 and CH129 mAbs were added to Colo205, HCT-15, BxPC3 and LS180 and binding was detected by indirect immunofluorescence analysis and flow cytometric analysis (figure7). Both FG129 and CH129 bound to the high expressing cell lines with Kd of 6-20nM and to low expressing cell lines with a Kd of 30-50nM. This is higher than binding to sialyl lewis a -HSA and probably reflects the complexity of glycan exression on the cell surface.
  • SABC antigen density
  • the mAbs were screened for their ability to act as a drug carrier by internalising and delivering drug to lysosomes.
  • Cellular internalisation was assessed by confocal microscopy, which showed internalisation of both 129 mAbs over a period of 90 minutes and co-localisation within the lysosomes.
  • the nucleus was stained in blue, plasma membrane in red, lysosomal compartments in purple and the 129 antibodies in green. Internalisation is seen on high cell surface antigen density colorectal cell lines Colo205 and HCT-15 and on pancreatic cell line BxPC3 ( Figure 10a and b).
  • CH129 would make a promising ADC candidate in a clinical setting
  • the mab was chemically conjugated to different payload/linker constructs that were pre-clinically and clinically validated.
  • three CH129 constructs were produced by ADC Biotechnology: one with the auristatin MMAE linked via a cleavable dipeptide valine- citruline linker and a para-aminobenzylalcohol (PABA) self-immolative spacer (CH129- vcE), one with the DM4 maytansinoid linked via the intermediately cleavable hindered disulphide linker SPDB (CH129-DM4) and one with the DM1 maytansinoid linked through the non-cleavable SMCC linker (CH129-DM1).
  • PABA para-aminobenzylalcohol
  • a matched set of control ADC constructs was also produced using the non-targeting mab Rituximab, to be used in relevant assay controls. Cytotoxicity was studied on two colorectal cell lines Colo205 and HCT-15 that express high cell surface densities of the targeted antigen sialyl-lewis-a.
  • CH129-ADC constructs give high in vitro target dependant efficacy. Results show a dose dependant decrease in cell death directly related with the decrease in antibody concentration on both cell lines. Cell killing was also target dependent, with higher killing being seen on the higher antigen expressing cell line Colo205, compared to HCT-15. On Colo205 ( Figure l ie) all three CH129-ADC constructs gave 100% cell killing with the vcE construct giving the highest efficacy (Ec50 ⁇ 10 "11M ) followed by the DM1 and DM4 constructs showing similar efficacy (Ec50s ⁇ 10 "10 M).
  • the ADC constructs were tested on a mixture of antigen positive and antigen negative cells, and as well on cell lines with heterogeneous tumour antigen expression.
  • ADCs with cleavable linkers give bystander killing compared with uncleavable linkers.
  • the bystander killing effect of the ADC constructs was evaluated on different cell ratio mixtures of high tumour antigen expressing cells Colo205 with cells that do not express the antigen - AGS.
  • Cells were mixed at ratios of 2: 1, 5: 1 and 10: 1 AGS to Colo205. Colo205 only, and AGS only were used as positive and negative controls respectively. Since AGS is an antigen negative cell line, the killing see on this cell line is non-specific, therefore concentrations at which killing is observed on AGS were not considered when assessing bystander killing. Specific killing is shown in Figures l lg, l lh and Hi highlighted by the rectangle.
  • DM1 was the most stable in this aspect, as it showed killing at concentrations higher than ⁇ , while DM4 at 3nM and vcE were less stable showing non-specific killing from InM.
  • DM1 is linked with a non-cleavable linker, it consisted the negative control for bystander killing.
  • the difference between the killing given by DM1 and DM4/vcE at the circled concentrations could be due to bystander killing.
  • DM4 gave a specific killing of -90%, vcE of -50-80% while DM1 of -20% of the cells.
  • Antigen positive patient sera also reduced binding (Gm 600-1000) as did antigen negative patent sera (Gm 650-1500). Even though FG129 was pre-incubated with the pancreatic sera, the mAb showed a strong preference for binding to the cells and not to the secreted antigen from the sera (Figure 12b). This suggests that secreted antigen should not prevent FG129 from localising within tumours.
  • the FG129 antibody makes an attractive candidate to be used in the context of a chimeric antigen receptor (CAR) as a scFv in order to induce anti-tumour T cell responses.
  • CAR chimeric antigen receptor
  • the heavy chain and light chain variable region were incorporated in silico into a single scFv sequence in the orientation: leader, heavy chain variable domain, spacer (3x GGGGS), light chain variable domain, spacer (6x Ala); purification tag (6x His) and synthesized ( Figure 13a).
  • Expi293 cells were transfected and allowed to produce protein transiently (6 days). His-tagged scFv was purified from Expi-293 supernatant using immobilised cobalt chromatography. The scFv was then characterised in terms of its binding properties to the sialyl-Lewis-a antigen or to cells expressing the antigen.
  • the antigen binding affinity of the FG129-scFv was measured by SPR and by ELISA on sialyl-Lewis-a.
  • Antigen binding affinity was also measured by SPR which gave a Kd of 10 "7 M (Table 1).
  • the FG129-scFv showed a high binding (Gm -400) and gave a dose dependent response with a submicromolar Kd (10 "7 M) ( Figure 13c).
  • aat acc tac gec atg aac tgg gtc cgc cag get cca gga aag ggt ttg gaa tgg gtt get cgc ata aga agt aaa agt aat aat tat gca aca tat tat gee gat tea gtg aaa ...
  • aat acc tac gee atg aac tgg gtc cgc cag get cca gga aag ggt ttg gaa tgg gtt get cgc ata aga agt aaa agt aat aat tat gca aca tat tat gee gat tea gtg aaa ...
  • Figure la Complete amino acid sequence of mouse FGl 29/29 IgGl heavy chain.
  • Figure lb Complete amino acid sequence of mouse FG129/29 kappa chain.
  • Figure 2b Complete amino acid sequence of mouse FGl 29/29 kappa chain variable region chimerised to human kappa chain constant region.
  • Varki A Kannagi R, Toole BP. Glycosylation Changes in Cancer.
  • Varki A Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology. 2010/03/20 ed: Cold Spring Harbor (NY); 2009.
  • Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
  • Clinical cancer research an official journal of the American Association for Cancer Research. 2015;21 :622-31.
  • BLAST and PSI-BLAST a new generation of protein database search programs. Nucleic acids research. 1997;25:3389-402.
  • Torelli A Robotti CA. ADVANCE and ADAM: two algorithms for the analysis of global similarity between homologous informational sequences. Computer applications in the biosciences : CABIOS. 1994;10:3-5.
  • Reff ME High-level production of recombinant immunoglobulins in mammalian cells.
  • FMGT the international ImMunoGeneTics information system. Nucleic acids research. 2009;37:D1006-12.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PCT/GB2016/052647 2015-08-25 2016-08-25 Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto Ceased WO2017033020A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP16760541.9A EP3341412B1 (en) 2015-08-25 2016-08-25 Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
US15/754,882 US10835618B2 (en) 2015-08-25 2016-08-25 Sialyl-di-Lewisa as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
ES16760541T ES2788159T3 (es) 2015-08-25 2016-08-25 Sialil-di-Lewisa tal como se expresa en las glucoproteínas pero no en los glucolípidos como diana funcional del cáncer y sus anticuerpos
BR112018003779-6A BR112018003779A2 (pt) 2015-08-25 2016-08-25 sialil-di-lewis a conforme expresso em glicoproteínas, mas não glicolipídios, como um alvo de câncer funcional e anticorpos para o mesmo
JP2018510883A JP6928602B2 (ja) 2015-08-25 2016-08-25 機能的な癌標的として、糖脂質ではなく糖タンパク質上で発現させたシアリル−ジ−ルイスａ及びそれに対する抗体
KR1020187008554A KR102713512B1 (ko) 2015-08-25 2016-08-25 기능성 암 표적 및 이에 대한 항체로서 당지질이 아닌 당단백질 상에 발현되는 시알릴-다이-루이스a
CA2996436A CA2996436A1 (en) 2015-08-25 2016-08-25 Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
DK16760541.9T DK3341412T3 (da) 2015-08-25 2016-08-25 Sialyl-di-lewis a som udtrykt på glycoproteins, men ikke glycolipider som funktionelt cancermål og antistoffer dertil
CN201680056234.5A CN108137695B (zh) 2015-08-25 2016-08-25 作为功能性癌症靶标的、不在糖脂而在糖蛋白上表达的唾液酸化二路易斯a及其抗体
ZA2018/01994A ZA201801994B (en) 2015-08-25 2018-03-26 Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1515094.9 2015-08-25
GBGB1515094.9A GB201515094D0 (en) 2015-08-25 2015-08-25 Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto

Publications (1)

Publication Number Publication Date
WO2017033020A1 true WO2017033020A1 (en) 2017-03-02

Family

ID=54292175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2016/052647 Ceased WO2017033020A1 (en) 2015-08-25 2016-08-25 Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto

Country Status (13)

Country Link
US (1) US10835618B2 (enExample)
EP (1) EP3341412B1 (enExample)
JP (1) JP6928602B2 (enExample)
KR (1) KR102713512B1 (enExample)
CN (1) CN108137695B (enExample)
BR (1) BR112018003779A2 (enExample)
CA (1) CA2996436A1 (enExample)
DK (1) DK3341412T3 (enExample)
ES (1) ES2788159T3 (enExample)
GB (1) GB201515094D0 (enExample)
PT (1) PT3341412T (enExample)
WO (1) WO2017033020A1 (enExample)
ZA (1) ZA201801994B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081988A1 (en) * 2018-10-19 2020-04-23 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptor targeting sialyl lewis a and uses thereof
WO2021019094A1 (en) 2019-07-31 2021-02-04 Scancell Limited Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
WO2023133452A1 (en) * 2022-01-06 2023-07-13 PTM Therapeutics, Inc. Methods of treating solid tumors and compositions thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906945A3 (en) * 2013-08-26 2022-03-16 BioNTech Research and Development, Inc. Nucleic acids encoding human antibodies to sialyl-lewis a
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015053871A2 (en) * 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015053871A2 (en) * 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. TSUCHIDA ET AL: "Synthesis of Disialyl Lewis a (Lea) Structure in Colon Cancer Cell Lines by a Sialyltransferase, ST6GalNAc VI, Responsible for the Synthesis of -Series Gangliosides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 25, 13 June 2003 (2003-06-13), US, pages 22787 - 22794, XP055319588, ISSN: 0021-9258, DOI: 10.1074/jbc.M211034200 *
BERGQUIST JOHN R ET AL: "Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study", JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, COLLEGE, CHICAGO, IL, US, vol. 223, no. 1, 23 February 2016 (2016-02-23), pages 52 - 65, XP029622727, ISSN: 1072-7515, DOI: 10.1016/J.JAMCOLLSURG.2016.02.009 *
JAMIE HEIMBURG-MOLINARO ET AL: "Cancer vaccines and carbohydrate epitopes", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 48, 6 September 2011 (2011-09-06), pages 8802 - 8826, XP028326010, ISSN: 0264-410X, [retrieved on 20110922], DOI: 10.1016/J.VACCINE.2011.09.009 *
K. MIYAZAKI: "Loss of Disialyl Lewisa, the Ligand for Lymphocyte Inhibitory Receptor Sialic Acid-Binding Immunoglobulin-Like Lectin-7 (Siglec-7) Associated with Increased Sialyl Lewisa Expression on Human Colon Cancers", CANCER RESEARCH, vol. 64, no. 13, 1 July 2004 (2004-07-01), US, pages 4498 - 4505, XP055319434, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-03-3614 *
PHILIP W NOBLE: "Characterisation of anti-glycan monoclonal antibodies", 1 January 2011 (2011-01-01), pages 1 - 246, XP055319650, Retrieved from the Internet <URL:http://eprints.nottingham.ac.uk/12071/1/Final_Thesis_for_Submission_16.6.11.pdf> [retrieved on 20161115] *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081988A1 (en) * 2018-10-19 2020-04-23 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptor targeting sialyl lewis a and uses thereof
WO2021019094A1 (en) 2019-07-31 2021-02-04 Scancell Limited Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
WO2023133452A1 (en) * 2022-01-06 2023-07-13 PTM Therapeutics, Inc. Methods of treating solid tumors and compositions thereof

Also Published As

Publication number Publication date
CN108137695A (zh) 2018-06-08
ZA201801994B (en) 2019-01-30
ES2788159T3 (es) 2020-10-20
BR112018003779A2 (pt) 2018-09-25
EP3341412B1 (en) 2020-03-25
DK3341412T3 (da) 2020-05-18
EP3341412A1 (en) 2018-07-04
PT3341412T (pt) 2020-05-21
JP6928602B2 (ja) 2021-09-01
CA2996436A1 (en) 2017-03-02
US20180236095A1 (en) 2018-08-23
US10835618B2 (en) 2020-11-17
JP2018529328A (ja) 2018-10-11
KR20180100541A (ko) 2018-09-11
GB201515094D0 (en) 2015-10-07
CN108137695B (zh) 2022-03-29
KR102713512B1 (ko) 2024-10-04

Similar Documents

Publication Publication Date Title
US11739159B2 (en) Antibody binding specifically to MUC1 and use thereof
TW201909926A (zh) Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
TW201132352A (en) Anti-GCC antibody molecules and related compositions and methods
JP2015221793A (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体
EP3341412B1 (en) Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
TW202216784A (zh) 抗ｃｄ３抗體以及其用途
EP3063160B1 (en) Glycans as functional cancer targets and antibodies thereto
EP4004056B1 (en) Anti-lewis y antibodies and uses thereof in cancer therapy
CN114729057B (zh) 抗岩藻糖基-gm1抗体
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
TW202400651A (zh) 抗cd200r1抗體
AU2022434346A1 (en) Antibody specifically binding to muc-1 and uses thereof
CN120795159A (zh) 抗Trop-2抗体及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16760541

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2996436

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15754882

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2018510883

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11201801543P

Country of ref document: SG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187008554

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016760541

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018003779

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018003779

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180226